Viva Biotech HoldingsFRA:VB0 +2.59%47 Net Margin % is 10.91% as of Dec. 2025, which is 17% below its 10-year median of 13.19. GuruFocus rates FRA:VB0 with a GF Score™ of 47/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 944 Biotechnology companies, Viva Biotech Holdings ranks better than 82.31% on this metric.
The historical rank and industry rank for Viva Biotech Holdings's Net Margin % or its related term are showing as below:
FRA:VB0'
s Net Margin % Range Over the Past 10 Years
Min: -55.51 Med: 13.19 Max: 82.3
Current: 12.7
FRA:VB0's Net Margin % is ranked better than 82.31% of 944
companies
in the Biotechnology industry
Industry Median: -88.815
vs FRA:VB0: 12.70
Viva Biotech Holdings (FRA:VB0) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Viva Biotech Holdings Net Margin % Related Terms
Viva Biotech Holdings Net Margin % Historical Data
* Premium members only.
The historical data trend for Viva Biotech Holdings's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VB0 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Viva Biotech Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Net Margin % distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viva Biotech Holdings (FRA:VB0) has a Net Margin % of 10.91% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Viva Biotech Holdings and its competitors. This is 17% below median its historical median of 13.19. According to the industry distribution chart, Viva Biotech Holdings ranks #167 out of 944 companies in the Biotechnology industry, placing it in the top 17.7%.
Is Viva Biotech Holdings' Net Margin % too high?
Viva Biotech Holdings' current Net Margin % of 10.91% is 17% below median its 10-year median of 13.19. Based on the distribution chart, Viva Biotech Holdings ranks #167 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Viva Biotech Holdings has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Viva Biotech Holdings ranks #167 out of 944 companies for Net Margin %. This places Viva Biotech Holdings in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Viva Biotech Holdings and its competitors. Viva Biotech Holdings's current Net Margin % is 10.91%, which is 17% below median its own 10-year median of 13.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.12 — trading 48.8% above its estimated fair value. The current Net Margin % is 10.91%, which is 17% below median its 10-year median of 13.19. Viva Biotech Holdings' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current Net Margin % is 10.91% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?
Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued.
The current stock price of €0.12 is trading 48.8% above its estimated GF Value™ of €0.08.
GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.
Key valuation signals for FRA:VB0:
Net Margin %: 10.91% (17% below median its 10-year median of 13.19)
GF Value™: €0.08 vs. price of €0.12 (48.8% above fair value)
No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
47GF Score
Get the complete analysis for FRA:VB0
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB0 has been successfully added to your 
